Serum Vascular Adhesion Protein-1 Predicts End-Stage Renal Disease in Patients with Type 2 Diabetes

Hung Yuan Li; Hung An Lin; Feng Jung Nien; Vin Cent Wu; Yi Der Jiang; Tien Jyun Chang; Hsien Li Kao; Mao Shin Lin; Jung Nan Wei; Cheng Hsin Lin; Shyang Rong Shih; Chi Sheng Hung; Lee Ming Chuang

doi:10.1371/journal.pone.0147981

Serum Vascular Adhesion Protein-1 Predicts End-Stage Renal Disease in Patients with Type 2 Diabetes

Hung Yuan Li, Hung An Lin, Feng Jung Nien, Vin Cent Wu, Yi Der Jiang, Tien Jyun Chang, Hsien Li Kao, Mao Shin Lin, Jung Nan Wei, Cheng Hsin Lin, Shyang Rong Shih, Chi Sheng Hung, Lee Ming Chuang

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Abstract

Background Diabetes is the leading cause of end-stage renal disease (ESRD) worldwide. Vascular adhesion protein-1 (VAP-1) participates in inflammation and catalyzes the deamination of primary amines into aldehydes, hydrogen peroxide, and ammonia, both of which are involved in the pathogenesis of diabetic complications. We have shown that serum VAP-1 is higher in patients with diabetes and in patients with chronic kidney disease (CKD), and can predict cardiovascular mortality in subjects with diabetes. In this study, we investigated if serum VAP-1 can predict ESRD in diabetic subjects. Methods In this prospective cohort study, a total of 604 type 2 diabetic subjects were enrolled between 1996 to 2003 at National Taiwan University Hospital, Taiwan, and were followed for a median of 12.36 years. The development of ESRD was ascertained by linking our database with the nationally comprehensive Taiwan Society Nephrology registry. Serum VAP-1 concentrations at enrollment were measured by time-resolved immunofluorometric assay. Results Subjects with serum VAP-1 in the highest tertile had the highest incidence of ESRD (p

Original language	English
Article number	e0147981
Journal	PLoS One
Volume	11
Issue number	2
DOIs	https://doi.org/10.1371/journal.pone.0147981
Publication status	Published - Feb 1 2016

ASJC Scopus subject areas

Agricultural and Biological Sciences(all)
Biochemistry, Genetics and Molecular Biology(all)
Medicine(all)

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1371/journal.pone.0147981

Fingerprint Dive into the research topics of 'Serum Vascular Adhesion Protein-1 Predicts End-Stage Renal Disease in Patients with Type 2 Diabetes'. Together they form a unique fingerprint.

Cite this

Serum Vascular Adhesion Protein-1 Predicts End-Stage Renal Disease in Patients with Type 2 Diabetes. / Li, Hung Yuan; Lin, Hung An; Nien, Feng Jung; Wu, Vin Cent; Jiang, Yi Der; Chang, Tien Jyun; Kao, Hsien Li; Lin, Mao Shin; Wei, Jung Nan; Lin, Cheng Hsin; Shih, Shyang Rong; Hung, Chi Sheng; Chuang, Lee Ming.

In: PLoS One, Vol. 11, No. 2, e0147981, 01.02.2016.

Research output: Contribution to journal › Article › peer-review

@article{dfa1810bdda748ea86b62a93ed1afb05,

title = "Serum Vascular Adhesion Protein-1 Predicts End-Stage Renal Disease in Patients with Type 2 Diabetes",

abstract = "Background Diabetes is the leading cause of end-stage renal disease (ESRD) worldwide. Vascular adhesion protein-1 (VAP-1) participates in inflammation and catalyzes the deamination of primary amines into aldehydes, hydrogen peroxide, and ammonia, both of which are involved in the pathogenesis of diabetic complications. We have shown that serum VAP-1 is higher in patients with diabetes and in patients with chronic kidney disease (CKD), and can predict cardiovascular mortality in subjects with diabetes. In this study, we investigated if serum VAP-1 can predict ESRD in diabetic subjects. Methods In this prospective cohort study, a total of 604 type 2 diabetic subjects were enrolled between 1996 to 2003 at National Taiwan University Hospital, Taiwan, and were followed for a median of 12.36 years. The development of ESRD was ascertained by linking our database with the nationally comprehensive Taiwan Society Nephrology registry. Serum VAP-1 concentrations at enrollment were measured by time-resolved immunofluorometric assay. Results Subjects with serum VAP-1 in the highest tertile had the highest incidence of ESRD (p",

author = "Li, {Hung Yuan} and Lin, {Hung An} and Nien, {Feng Jung} and Wu, {Vin Cent} and Jiang, {Yi Der} and Chang, {Tien Jyun} and Kao, {Hsien Li} and Lin, {Mao Shin} and Wei, {Jung Nan} and Lin, {Cheng Hsin} and Shih, {Shyang Rong} and Hung, {Chi Sheng} and Chuang, {Lee Ming}",

year = "2016",

month = feb,

day = "1",

doi = "10.1371/journal.pone.0147981",

language = "English",

volume = "11",

journal = "PLoS One",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "2",

}

TY - JOUR

T1 - Serum Vascular Adhesion Protein-1 Predicts End-Stage Renal Disease in Patients with Type 2 Diabetes

AU - Li, Hung Yuan

AU - Lin, Hung An

AU - Nien, Feng Jung

AU - Wu, Vin Cent

AU - Jiang, Yi Der

AU - Chang, Tien Jyun

AU - Kao, Hsien Li

AU - Lin, Mao Shin

AU - Wei, Jung Nan

AU - Lin, Cheng Hsin

AU - Shih, Shyang Rong

AU - Hung, Chi Sheng

AU - Chuang, Lee Ming

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background Diabetes is the leading cause of end-stage renal disease (ESRD) worldwide. Vascular adhesion protein-1 (VAP-1) participates in inflammation and catalyzes the deamination of primary amines into aldehydes, hydrogen peroxide, and ammonia, both of which are involved in the pathogenesis of diabetic complications. We have shown that serum VAP-1 is higher in patients with diabetes and in patients with chronic kidney disease (CKD), and can predict cardiovascular mortality in subjects with diabetes. In this study, we investigated if serum VAP-1 can predict ESRD in diabetic subjects. Methods In this prospective cohort study, a total of 604 type 2 diabetic subjects were enrolled between 1996 to 2003 at National Taiwan University Hospital, Taiwan, and were followed for a median of 12.36 years. The development of ESRD was ascertained by linking our database with the nationally comprehensive Taiwan Society Nephrology registry. Serum VAP-1 concentrations at enrollment were measured by time-resolved immunofluorometric assay. Results Subjects with serum VAP-1 in the highest tertile had the highest incidence of ESRD (p

AB - Background Diabetes is the leading cause of end-stage renal disease (ESRD) worldwide. Vascular adhesion protein-1 (VAP-1) participates in inflammation and catalyzes the deamination of primary amines into aldehydes, hydrogen peroxide, and ammonia, both of which are involved in the pathogenesis of diabetic complications. We have shown that serum VAP-1 is higher in patients with diabetes and in patients with chronic kidney disease (CKD), and can predict cardiovascular mortality in subjects with diabetes. In this study, we investigated if serum VAP-1 can predict ESRD in diabetic subjects. Methods In this prospective cohort study, a total of 604 type 2 diabetic subjects were enrolled between 1996 to 2003 at National Taiwan University Hospital, Taiwan, and were followed for a median of 12.36 years. The development of ESRD was ascertained by linking our database with the nationally comprehensive Taiwan Society Nephrology registry. Serum VAP-1 concentrations at enrollment were measured by time-resolved immunofluorometric assay. Results Subjects with serum VAP-1 in the highest tertile had the highest incidence of ESRD (p

UR - http://www.scopus.com/inward/record.url?scp=84958987221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958987221&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0147981

DO - 10.1371/journal.pone.0147981

M3 - Article

C2 - 26845338

AN - SCOPUS:84958987221

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0147981

ER -

Serum Vascular Adhesion Protein-1 Predicts End-Stage Renal Disease in Patients with Type 2 Diabetes

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this